Long-term effects on bone mineral density and bone metabolism of 6 months’ treatment with gonadotropin-releasing hormone analogues in Japanese women: comparison of buserelin acetate with leuprolide acetate

Our objective was to assess the effects of 6 months’ treatment with two types of gonadotropin-releasing hormone (GnRH) analogues on lumbar bone mineral density (BMD) and bone metabolism. We studied 27 women who had been given a diagnosis of endometriosis or uterine myoma. The subjects received drug therapy for 6 months and were subsequently followed up for 1 year. The BMD of the lumbar spine (L2, L3, L4) was measured by dual energy X-ray absorptiometry four times: at baseline, after 6 months, after 12 months, and after 18 months. The serum concentrations of sex steroids and bone metabolic markers were measured at the same times as BMD. Compared with the baseline value, the mean decrease in the buserelin group L2–4 BMD was 3.7% at 6 months, 1.7% at 12 months, and 0.4% at 18 months. In the leuprolide group, L2–4 BMD decreased respectively by 5.1%, 6.2%, and 4.3%. Serum concentrations of calcium increased significantly after 6 months of treatment (P < 0.05) and returned to the baseline level at 12 months in both groups. In the leuprolide group, the intact osteocalcin concentration after 6 months was significantly higher than the baseline value, and after 12 months, it decreased to the baseline level. Our results indicate that the effect on BMD of 6 months’ treatment with GnRH analogues virtually resolves by 1 year after treatment, provided that drugs affecting bone metabolism are not given during this period. Similar content being viewed by others

LO David AP Elizabeth (2001) ArticleTitleTreatment of endometriosis N Eng J Med 345 266–275 Occurrence Handle10.1056/NEJM200107263450407 RL Barbieri (1988) ArticleTitleNew therapy for endometriosis N Eng J Med 318 512–514 WH Matta RW Shaw R Hesp R Evans (1988) ArticleTitleReversible trabecular bone density loss following induced hypooestrogenism with the GnRH analog buserelin in premenopausal women Clin Endocrinol 29 45–51 WH Matta I Stabile RW Shaw S Campbell (1988) ArticleTitleDoppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin-releasing hormone, buserelin Fertil Steril 49 1083–1085 Occurrence Handle2967195 JP Devogelaer CN DeDeuxchaisnes J Donnez K Thomas (1987) ArticleTitleLHRH analogues and bone loss Lancet i 1498 Occurrence Handle10.1016/S0140-6736(87)92255-0 T Nencionii M Penotti M Barbieri-Carones S Ortolani C Trevisan F Polvani (1991) ArticleTitleGonadotropin releasing hormone agonist therapy and its effect on bone mass Gynecol Endocrinol 5 49–56 Occurrence Handle1910246 MF Dawood (1993) ArticleTitleImpact of medical treatment of endometriosis on bone mass Am J Obstet Gynecol 168 674–684 Occurrence Handle8438949 JA Johansen BJ Riis C Hassager M Moen J Jacobson C Christiansen (1988) ArticleTitleThe effects of a gonadotropin releasing hormone agonist analog (nafarelin) on bone metabolism J Clin Endocrinol Metab 67 701–706 Occurrence Handle2971080 RW Whitehouse JE Adams K Bancroft CA Vaughan-Williams M Elstein (1990) ArticleTitleThe effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis Clin Endocrinol 33 365–373 IS Tummon (1989) ArticleTitleA randomized, prospective comparison of endocrine changes induced with intranasal leuprolide or danazol for treatment of endometriosis Fertil Steril 51 390–394 Occurrence Handle2522062 MD Damewood WD Schlaff JS Hesla JA Rock (1989) ArticleTitleInterval bone mineral density with long-term gonadotropin releasing hormone agonist suppression Fertil Steril 52 596–599 Occurrence Handle2680617 RS Rittmaster DL Tompson (1990) ArticleTitleEffect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism J Clin Endocrinol Metab 70 1096–1102 Occurrence Handle2156885 JC Stevenson B Lees R Gardner RW Shaw (1989) ArticleTitleA comparison of the skeletal effects of goserelin and danazol in premenopausal women with endometriosis Horm Res 32 161–164 Occurrence Handle2533148 S Dodin A Lemay R Maheux M Dumont L Turcot-Lemay (1991) ArticleTitleBone mass in endometriosis patients treated with GnRH agonist implant or danazol Obstet Gynecol 77 410–415 Occurrence Handle1825135 ES Orwoll AA Yuzpe KA Burry L Heinrichs VC Buttram SuffixJr MD Hornstein (1994) ArticleTitleNafarelin therapy in endometriosis: long-term effects on bone mineral density Am J Obstet Gynecol 171 1221–275 Occurrence Handle7977523 ES Surrey HL Ludd (1992) ArticleTitleReduction of vasomotor symptoms and bone mineral density loss with combined norehindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial J Clin Endocrinol Metab 75 558–563 Occurrence Handle10.1210/jc.75.2.558 Occurrence Handle1386374 AR Scialli KJ Jestila JA Simon (1993) ArticleTitleLeuprolide acetate and bone mineral density measured by quantitative digitized radiography Fertil Steril 59 674–676 Occurrence Handle8458476 AT Leather JWW Studd NR Watson EFN Holland (1993) ArticleTitleThe prevention of bone loss in young women treated with GnRH analogues with “add-back” oestrogen therapy Obstet Gynecol 81 104–107 Occurrence Handle8416441 JM Wheeler JD Knittle JD Miller (1992) ArticleTitleDepot leuprolide versus danazol in treatment of women with symptomatic endometriosis Am J Obstet Gynecol 167 1367–1371 Occurrence Handle1442992 JA Rock JA Truglia RJ Caplan InstitutionalAuthorNameand the Zoladex Endometriosis Study Group (1993) ArticleTitleZoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol Obstet Gynecol 82 198–205 Occurrence Handle8336864 BJ Riis C Christiansen J Johansen J Jacobson (1990) ArticleTitleIs it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists? J Clin Endocrinol Metab 70 920–924 Occurrence Handle2138631 R Revilla M Revilla ER Hernandez LF Villa L Varela H Rico (1995) ArticleTitleEvidence that the loss of bone mass induced by GnRH agonists is not totally recovered Maturitas 22 145–150 Occurrence Handle10.1016/0378-5122(95)00929-F Occurrence Handle8538483 AM Paoletti S Guerriero GG Serra E Solla A Cagnacci GB Melis AMB Vacca (1996) ArticleTitleSpontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment Fertil Steril 65 707–710 Occurrence Handle8654625 KS Moghissi WD Schlaff DL Olive MA Skinner H Yin (1998) ArticleTitleGoserelin acetate (Zoladex) with or without hormone replacement therapy for the treatment of endometriosis Fertil Steril 69 1056–1062 Occurrence Handle10.1016/S0015-0282(98)00086-7 Occurrence Handle9627292 H Matsuo S Yamabe T Otani S Motoyama K Katayama T Shimura M Mochizuki Y Ueda K Takeuchi M Bou T Maruo (2000) ArticleTitleChanges in bone metabolism for 12 months after gonadotropin-releasing hormone agonist treatment for endometriosis Acta Obstet Gynaec Jpn 52 659–668 JA Gudmundsson S Ljunghall C Berquist L Wide SJ Nillius (1987) ArticleTitleIncreased bone turnover during gonadotropin-releasing hormone superagonist-induced ovulation inhibition J Clin Endocrinol Metab 65 159–163 Occurrence Handle2953749 O Ylikorkala CG Nilsson E Hirvonen L Viinikka (1990) ArticleTitleEvidence of similar increases in bone turnover during nafarelin and danazol use in women with endometriosis Gynecol Endocrinol 4 251–260 Occurrence Handle2150580 EY Adashi (1994) ArticleTitleLong-term gonadotropin-releasing hormone agonist therapy: the evolving issue of steroidal “add-back” paradigms Hum Reprod Update 9 1380–1397 Author information Authors and Affiliations Corresponding author About this article Cite this article Makita, K., Ishitani, K., Ohta, H. et al. Long-term effects on bone mineral density and bone metabolism of 6 months’ treatment with gonadotropin-releasing hormone analogues in Japanese women: comparison of buserelin acetate with leuprolide acetate. J Bone Miner Metab 23, 389–394 (2005). https://doi.org/10.1007/s00774-005-0618-3 Received: Accepted: Issue date: DOI: https://doi.org/10.1007/s00774-005-0618-3